Holen Sie sich die Stockscreener-App
6.84
2.24%
0.15
Handel nachbörslich:
6.84
Schlusskurs vom Vortag:
$6.69
Offen:
$6.65
24-Stunden-Volumen:
1.02M
Relative Volume:
0.97
Marktkapitalisierung:
$414.44M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.5266
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
-29.56%
1M Leistung:
-17.79%
6M Leistung:
-38.65%
1J Leistung:
-17.19%
1-Tages-Spanne:
$6.60
$7.12
1-Wochen-Bereich:
$6.3526
$8.27
52-Wochen-Spanne:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
6.84 | 405.35M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Ginkgo Bioworks Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:DNA) 2026-03-03 - Seeking Alpha
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2025 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure - AI Insider
Ginkgo Bioworks Launches Ginkgo Cloud Lab to Provide Remote Access for Researchers - marketscreener.com
Ginkgo Bioworks Makes Major Pivot (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Launches Ginkgo Cloud Lab - marketscreener.com
DNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture - Sahm
DNA SEC FilingsGinkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration - Yahoo Finance
DNABW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ginkgo Bioworks Q4 Earnings Call Highlights - MarketBeat
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of Its Non-Core Biosecurity Business - 富途牛牛
Ginkgo Bioworks Holdings Inc (DNA) Q4 2025 Earnings Call Highlights: Strategic Shifts and ... By GuruFocus - Investing.com Canada
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter - Benzinga
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business - The Malaysian Reserve
Ginkgo Bioworks Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ginkgo Bioworks Divests Biosecurity Unit, Retains Minority Stake - TipRanks
Ginkgo Bioworks to Sell Biosecurity Unit to Tower Biosecurity, Retaining 20% Equity Stake - TradingView
Ginkgo Bioworks (NYSE: DNA) trades Biosecurity arm for 20% Tower stake - Stock Titan
Ginkgo Bioworks to sell biosecurity unit for 20% stake in Tower Biosecurity - StreetInsider
Ginkgo Bioworks Q4 2025 Earnings Call Transcript - MarketBeat
Erste Asset Management GmbH Acquires 200,000 Shares of Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Ginkgo Bioworks Q4 Loss Profile Reinforces Bearish Narratives On Cash Burn And Profit Timing - Sahm
Ginkgo Bioworks (NYSE:DNA) Releases Quarterly Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Ginkgo Bioworks reports fourth quarter and full year 2025 financial results - marketscreener.com
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financ - GuruFocus
Ginkgo Bioworks Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Ginkgo Bioworks Q4 2025 sees improved cash management - Investing.com
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cost cuts narrow Ginkgo Bioworks (NYSE: DNA) 2025 net loss - Stock Titan
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business – Company Announcement - Financial Times
Ginkgo Bioworks 报告了截至 2025 年第四季度及全年的财务业绩，宣布将专注于自主实验室产品，并剥离其非核心的生物安全业务。 - 富途牛牛
Aug Outlook: Whats SILOs historical return2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Insights into Ginkgo Bioworks Holdings's Upcoming Earnings - Benzinga
Ginkgo Bioworks Holdings Inc (DNA) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Tech Rally: What are the future prospects of Ginkgo Bioworks Holdings Inc2025 Earnings Surprises & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
What are Ginkgo Bioworks Holdings Inc.’s recent SEC filings showing2025 Support & Resistance & Safe Capital Allocation Plans - mfd.ru
Ginkgo Bioworks Holdings, Inc. (DNA): Investor Outlook on a Biotechnology Innovator with a 3.20% Potential Upside - DirectorsTalk Interviews
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation - 富途牛牛
Ginkgo Bioworks Holdings, Inc. (DNA) stock dips while market gains: Key facts - MSN
Why (DNA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products - Investing News Network
Ginkgo Bioworks Signs Crop Protection Collaboration With Invaio - marketscreener.com
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Ginkgo Bioworks (DNA) to Release Earnings on Tuesday - MarketBeat
RSI Check: Is Ginkgo Bioworks Holdings Inc part of any major indexTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights - MSN
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
Does Ginkgo Bioworks Holdings Inc. stock reflect fundamentalsTrade Exit Report & Technical Entry and Exit Tips - mfd.ru
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):